Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Year: 2024
Type: supplementary-materials
Abstract: Supplementary Tables Supplementary Table 1: Patient and tumor sample information Supplementary Table 2: Tumor mutation burden Supplementary Table 3: Unfiltered whole exome sequencing mutation analysis Supplementary Table 4: Filtered whole exome sequencing mutation analysis Supplementary Table 5: Immunohistochemistry scores of tumors Supplementary Table 6: FACS panel for PBMC analysis Supplementary Table 7: Geometric mean fluorescence intensity (GMFI) from PBMC FACS Supplementary Table 8: Representativeness of Study Participants
Authors: H. Josh Jang, Galen Hostetter, Alexander W. MacFarlane, Zachary Madaj, Eric A. Ross, Toshinori Hinoue, Justin R. Kulchycki, Ryan S. Burgos, Mahvish Tafseer, R. Katherine Alpaugh, Candice L. Schwebel, Rutika Kokate, Daniel M. Geynisman, Matthew R. Zibelman, Pooja Ghatalia, Peter W. Nichols, Woonbok Chung, Jozef Madzo, Noah M. Hahn, David I. Quinn, Jean-Pierre J. Issa, Michael J. Topper, Stephen B. Baylin, Hui Shen, Kerry S. Campbell, Peter A. Jones, Elizabeth R. Plimack
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402797168